AU Patent

AU2019337703B2 — Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Assigned to Aerie Pharmaceuticals Inc · Expires 2023-02-02 · 3y expired

What this patent protects

Provided herein are amino isoquinolinyl amide and sulfonamide compounds that affect the function of kinases and other proteins in a cell and that are useful as therapeutic agents. In particular, these compounds are useful in the treatment of eye diseases such as glaucoma and reti…

USPTO Abstract

Provided herein are amino isoquinolinyl amide and sulfonamide compounds that affect the function of kinases and other proteins in a cell and that are useful as therapeutic agents. In particular, these compounds are useful in the treatment of eye diseases such as glaucoma and retinal diseases, as anti-inflammatory agents, for the treatment of cardiovascular diseases, and for diseases characterized by abnormal growth, such as cancers.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019337703B2
Jurisdiction
AU
Classification
—
Expires
2023-02-02
Drug substance claim
No
Drug product claim
No
Assignee
Aerie Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.